Evidence map›Paper›PMID 28467804›Full record

ArticleOncotarget2017

Androgen receptor status predicts development of brain metastases in ovarian cancers.

Gloria Mittica, Rebecca Senetta, Giulia Scotto, Massimo Aglietta, Furio Maggiorotto, Eleonora Ghisoni, Sofia Genta, Renzo Boldorini, Claudia Manini, Isabella Morra and 4 more

Open access · diamondAbstract readMulticenter Study
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Gloria MitticaDepartment of Oncology, University of Turin, Turin, Italy.
Rebecca SenettaUnit of Pathology Candiolo Cancer Institute-FPO- IRCCS, Candiolo, Italy.
Giulia ScottoDepartment of Oncology, University of Turin, Turin, Italy.
Massimo AgliettaDepartment of Oncology, University of Turin, Turin, Italy.
Furio MaggiorottoDivision of Gynecologic Oncology, Candiolo Cancer Institute-FPO- IRCCS, Candiolo, Italy.
Eleonora GhisoniDepartment of Oncology, University of Turin, Turin, Italy.
Sofia GentaDepartment of Oncology, University of Turin, Turin, Italy.
Renzo BoldoriniDepartment of Health Science, University of Eastern Piedmont "Amedeo Avogadro", Novara, Italy.
Claudia ManiniUnit of Pathology, Giovanni Bosco Hospital, Turin, Italy.
Isabella MorraUnit of Pathology, Città della Salute e della Scienza, Turin, Italy.
Roberta BuosiDivision of Oncology, Santo Spirito Hospital, Casale Monferrato, Italy.
Anna SapinoUnit of Pathology Candiolo Cancer Institute-FPO- IRCCS, Candiolo, Italy.
Paola CassoniDepartment of Medical Sciences, University of Turin, Turin, Italy.
Giorgio ValabregaDepartment of Oncology, University of Turin, Turin, Italy.
University of Turin · ITCandiolo Cancer Institute · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITOspedale di Santo Spirito · ITOspedale San Giovanni Bosco · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastases are uncommon localizations in epithelial ovarian cancer (EOC), their reported incidence is increasing and no predictive biomarkers have been identified yet. Goals of this study were: i) to define a possible association between Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR),human EGF receptor 2 (HER2) and brain progression in EOC patients, and ii) to identify differences in ER, PR, AR and HER2 protein expression from primary EOC and its matched resected brain metastasis. A retrospective series of 11 EOC with matched brain metastasis surgically removed was collected. For comparison, a "Control dataset" of 22 patients, without evidence of brain involvement after an adequate follow up was matched. ER, PR, AR and HER2 status were analyzed by means of immunohistochemistry forCases (both primary and metastatic lesions) and Controls.Univariate analysis showed that AR status was significantly associated with brain localization, both considered as discrete variable (cut-off: 10%, p=0.013) and as continuous one (p=0.035). Multivariate analysis confirmed this trend (p=0.053). When considered as continuous variables, ER and AR showed greater expression in primary tumors in comparison with brain metastases (p=0.013 and p=0.032, respectively).In our series, AR predicts brain involvement, with a 9.5 times higher propensity for AR-negative EOC. Moreover, brain dissemination is probably the result of progressive dedifferentiation of primary tumor, shown by reduction of ER and AR expression in metastases. Further studies are required, in order to anticipate and improve multimodal treatment of brain metastases.

Indexed as

AdultAgedBiomarkers, TumorBrain NeoplasmsCarcinoma, Ovarian EpithelialCase-Control StudiesErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunohistochemistryMiddle AgedMultivariate AnalysisNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisReceptors, AndrogenBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, AndrogenReceptors, EstrogenReceptors, Progesteroneandrogen receptorbrain metastasesovarian cancer

Identifiers

PMID28467804
PMCPMC5522232
OpenAlexW2606090144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.